Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$1.90 -0.5%	$1.94	$1.60 ▼ $2.54	$732.80M	1.04	1.34 million shs	885,477 shs
MLTX MoonLake Immunotherapeutics	$47.52 +0.5%	$41.82	$31.42 ▼ $58.26	$3.04B	1.23	384,473 shs	923,933 shs
VKTX Viking Therapeutics	$26.52 -5.9%	$27.19	$18.92 ▼ $81.73	$2.98B	0.65	4.02 million shs	6.32 million shs
XENE Xenon Pharmaceuticals	$32.40 +0.6%	$32.85	$26.74 ▼ $46.00	$2.49B	1.09	620,907 shs	13.15 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	0.00%	+2.15%	-7.32%	+6.15%	-18.10%
MLTX MoonLake Immunotherapeutics	0.00%	+9.24%	+21.97%	+19.22%	+18.24%
VKTX Viking Therapeutics	0.00%	+1.96%	-5.82%	+3.39%	-44.04%
XENE Xenon Pharmaceuticals	0.00%	+1.09%	+11.57%	-5.43%	-11.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	2.4709 of 5 stars	0.0	5.0	0.0	2.6	0.0	2.5
MLTX MoonLake Immunotherapeutics	2.2546 of 5 stars	3.5	1.0	0.0	3.3	2.5	0.0
VKTX Viking Therapeutics	4.3773 of 5 stars	4.5	1.0	4.7	1.4	3.3	0.0
XENE Xenon Pharmaceuticals	3.1219 of 5 stars	4.5	2.0	0.0	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	3.00	Buy	$74.50	56.78% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	228.63% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	69.19% Upside

Current Analyst Ratings Breakdown

Latest CRON, VKTX, XENE, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
6/3/2025	MLTX MoonLake Immunotherapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$67.00
5/19/2025	MLTX MoonLake Immunotherapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$61.00
5/14/2025	XENE Xenon Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$78.00 ➝ $80.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
5/13/2025	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $47.00
5/13/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
5/13/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	6.23	$0.00 per share	4,083.21	$2.90 per share	0.66
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$7.09 per share	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A
XENE Xenon Pharmaceuticals	$9.43M	263.63	N/A	N/A	$9.90 per share	3.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.13	14.62	63.33	32.31	39.69%	-0.07%	-0.07%	8/6/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.30	N/A	N/A	N/A	N/A	-30.81%	-28.40%	8/6/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$234.33M	-$3.23	N/A	N/A	N/A	N/A	-32.44%	-30.84%	8/6/2025 (Estimated)

Latest CRON, VKTX, XENE, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million
5/8/2025	Q1 2025	CRON Cronos Group	$0.01	$0.02	+$0.01	$0.02	$45.44 million	$33.62 million
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	27.80	26.75
MLTX MoonLake Immunotherapeutics	0.18	21.11	21.11
VKTX Viking Therapeutics	N/A	44.25	44.25
XENE Xenon Pharmaceuticals	N/A	17.66	17.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
MLTX MoonLake Immunotherapeutics	93.85%
VKTX Viking Therapeutics	76.03%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	7.30%
MLTX MoonLake Immunotherapeutics	12.02%
VKTX Viking Therapeutics	4.10%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	385.68 million	357.53 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.32 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.50 million	Optionable

CRON, VKTX, XENE, and MLTX Headlines

Recent News About These Companies

Xenon Pharmaceuticals Joins Russell 3000® and 2000® Indexes

June 27 at 6:10 PM | tipranks.com

Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution

June 27 at 4:16 PM | quiverquant.comQ

Xenon Joins the Russell 3000® and Russell 2000® Indexes

June 27 at 4:16 PM | financialpost.comF

Xenon Joins the Russell 3000® and Russell 2000® Indexes

June 27 at 4:01 PM | globenewswire.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 26 at 4:20 PM | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 26 at 4:01 PM | globenewswire.com

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)

June 26 at 2:58 AM | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Passes Below 50 Day Moving Average - What's Next?

June 25, 2025 | marketbeat.com

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

June 24, 2025 | globenewswire.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Down 3.4% - Here's Why

June 16, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from Analysts

June 15, 2025 | marketbeat.com

Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

June 12, 2025 | marketbeat.com

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

June 11, 2025 | zacks.com

Cantor Fitzgerald Estimates XENE FY2026 Earnings

June 10, 2025 | marketbeat.com

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

June 2, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DE

May 31, 2025 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2025 | globenewswire.com

Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)

May 30, 2025 | marketbeat.com

Fair Value analysis proves accurate as XENE drops 37% from February 2024 peak

May 21, 2025 | investing.com

Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday

May 15, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming
By Thomas Hughes | June 26, 2025
View Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming
Micron Joins Latest $200 Billion United States Investment
By Gabriel Osorio-Mazilli | June 16, 2025
View Micron Joins Latest $200 Billion United States Investment

CRON, VKTX, XENE, and MLTX Company Descriptions

Cronos Group NASDAQ:CRON

$1.90 -0.01 (-0.52%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.90 0.00 (-0.26%)

As of 06/27/2025 07:27 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

MoonLake Immunotherapeutics NASDAQ:MLTX

$47.52 +0.23 (+0.49%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$45.88 -1.65 (-3.46%)

As of 06/27/2025 04:44 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Viking Therapeutics NASDAQ:VKTX

$26.52 -1.65 (-5.86%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$26.60 +0.07 (+0.28%)

As of 06/27/2025 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Xenon Pharmaceuticals NASDAQ:XENE

$32.40 +0.20 (+0.62%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$32.39 -0.01 (-0.03%)

As of 06/27/2025 05:50 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time